USFDA issues EIR for OmniChem facility
Shares of pharma firm Granules India Ltd. on Friday gained 6.37% to close at ₹121.85 on the back of the U.S. Food and Drug Administration issuing the Establishment Inspection Report (EIR) for the OmniChem facility in Visakhapatnam. The facility, which manufactures API intermediates, is a 50:50 joint venture of Granules India and Ajinomoto OmniChem N.V. The USFDA has issued EIR for the facility, Granules said in a regulatory filing to the stock exchange.
The regulator had inspected the facility in December 2016 and made seven observations, the release said.